Crossmark Global Holdings Inc. Sells 549 Shares of Azenta, Inc. (NASDAQ:AZTA)

Crossmark Global Holdings Inc. decreased its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 12.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,987 shares of the company’s stock after selling 549 shares during the period. Crossmark Global Holdings Inc.’s holdings in Azenta were worth $210,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Peregrine Capital Management LLC lifted its holdings in shares of Azenta by 1.3% during the 2nd quarter. Peregrine Capital Management LLC now owns 97,043 shares of the company’s stock valued at $5,106,000 after buying an additional 1,259 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Azenta by 5.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,115,816 shares of the company’s stock worth $58,714,000 after purchasing an additional 56,387 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Azenta by 3.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 515,393 shares of the company’s stock valued at $27,120,000 after purchasing an additional 18,680 shares during the period. IMA Advisory Services Inc. bought a new stake in shares of Azenta during the 2nd quarter valued at about $1,486,000. Finally, Raymond James & Associates lifted its stake in shares of Azenta by 0.5% in the 2nd quarter. Raymond James & Associates now owns 110,948 shares of the company’s stock worth $5,838,000 after purchasing an additional 594 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Price Performance

Shares of NASDAQ:AZTA opened at $47.26 on Friday. The company has a market capitalization of $2.55 billion, a P/E ratio of -17.44 and a beta of 1.51. Azenta, Inc. has a 1-year low of $44.00 and a 1-year high of $69.16. The firm’s 50 day simple moving average is $53.28 and its two-hundred day simple moving average is $55.29.

Azenta (NASDAQ:AZTA) last released its earnings results on Tuesday, August 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.09. Azenta had a negative net margin of 23.66% and a positive return on equity of 0.89%. The company had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $166.14 million. During the same quarter in the previous year, the company earned $0.13 EPS. Azenta’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, sell-side analysts anticipate that Azenta, Inc. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZTA has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $69.00 target price on shares of Azenta in a research report on Wednesday, August 7th. Evercore ISI boosted their price objective on shares of Azenta from $52.00 to $53.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Azenta presently has a consensus rating of “Hold” and an average price target of $67.00.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.